CervoMed (CRVO) has released an update to notify the public and investors about its officers.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CervoMed Inc. has appointed the accomplished Joshua S. Boger, Ph.D., founder of Vertex Pharmaceuticals, as its new Chair of the Board and director. With an illustrious background including leadership roles at Vertex and Merck, as well as his current position at Alkeus Pharmaceuticals, Dr. Boger brings a wealth of experience to CervoMed. He holds a significant stake in the company, with shares and warrants just shy of 10%, further tying his interests to the company’s success following a recent merger. In recognition of his new role, Dr. Boger will receive an option grant for 10,000 shares, aligning his compensation with the performance of the company’s stock.
For further insights into CRVO corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
